Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Precision in Practice—Bringing Targeted Therapy to mHSPC
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
Tiffany Traina, MD, FASCO
Javier Cortes, MD, PhD
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
What’s Next for TROP2-Directed ADCs in TNBC?
The Power of Timing: Therapies That Change Outcomes
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
August 20, 2026
02:30 PM - 03:30 PM ET
September 24, 2026
03:30 PM - 04:30 PM ET
September 03, 2026
02:00 PM - 03:00 PM ET
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Chairperson’s Perspective: Incorporating Novel Treatment Options for Schizophrenia Into Clinical Practice - Overcoming Clinical Inertia
Jose Rubio, MD
EHA 2026: Long-Term Zanubrutinib Outcomes
Alessandra Tedeschi, MD
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Chan Y. Cheah, MBBS
De Novo mHSPC: Recognizing the Patients Who Need More
Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
Linda Stein Gold, MD
Lakshi Aldredge, MSN, ANP-BC
Najat M. Watch, PA
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
ADT Intensification: The Evidence You Can’t Afford to Miss
Targeting PTEN: Why It Matters
IBD Masterclass: Choosing the Right IBD Therapy - A Patient-Clinician Connection
Florence Odufalu, MD
Ugo Iroku, MD, MHS
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.